The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: A review

International Journal of Surgery

Volumn 3, Issue 4, 2005, Pages 278-285

  Sooriakumaran, P ^a   Kaba, R ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular risk; COX 2 inhibitors; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAFAZATROM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; ROFECOXIB; SULINDAC; THROMBOXANE SYNTHASE INHIBITOR;

ADENOMA; CANCER PREVENTION; CANCER RISK; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY INJURY; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE DYSFUNCTION; TISSUE DISTRIBUTION; UPREGULATION;

EID: 31144470864     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2005.10.002     Document Type: Review

References (65)

1. C. Parker Active surveillance: towards a new paradigm in the management of early prostate cancer Lancet Oncol 5 2004 101 106
2. A. Jemal, T. Murray, and A. Samuels Cancer statistics CA Cancer J Clin 53 2003 5 26
3. P.A. Kupelian, L. Potters, and J.P. Ciezki Radical prostatectomy, external beam radiotherapy <72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 54 2S2 2002 38 61
4. J. Javidan, A.D. Deitch, and X.B. Shi The androgen receptor and mechanisms of androgen independence Cancer Invest 23 6 2005 520 528
5. J.R. Vane, and Y.S. Bakhle Botting, cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120
6. W.L. Smith, R.M. Garavito, and D.L. DeWitt Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 J Biol Chem 271 1996 33157 33160
7. T. Hla, and D. Bishop-Bailey Cyclooxygenase-1 and -2 isoenzymes Int J Biochem Cell Biol 31 1999 551 557
8. M. Pairet, and G. Engelhardt Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications Fundam Clin Pharmacol 10 1996 1 17
9. S.A. Kraemer, E.A. Meade, and D.L. DeWitt Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 50-flanking regulatory sequences Arch Biochem Biophys 293 1992 391 400
10. J.C. Otto, and W.L. Smith Prostaglandin endoperoxide synthases-1 and -2 J Lipid Mediat Cell Signal 12 1995 139 156
11. M.M. Taketo Cyclooxygenase-2 inhibitors in tumorigenesis (part I) J Natl Cancer Inst 90 1998 529 536
12. M.M. Taketo Cyclooxygenase-2 inhibitors in tumorigenesis (part II) J Natl Cancer Inst 90 1998 1609 1620
13. E.M. Moran Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks J Environ Pathol Toxicol Oncol 21 2002 193 201
14. X.C. Xu COX-2 inhibitors in cancer treatment and prevention, a recent development Anticancer Drugs 13 2002 127 137
15. A.E. Norrish, R.T. Jackson, and C.U. McRae Non-steroidal anti-inflammatory drugs and prostate cancer progression Int J Cancer 77 1998 511 515
16. J.E. Nelson, and R.E. Harris Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study Oncol Rep 7 2000 169 170
17. R.O. Roberts, D.J. Jacobson, and C.J. Girman A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer Mayo Clin Proc 77 2002 219 225
18. M. Pollard, and P.H. Luckert The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells Prostate 8 1986 81 86
19. M. Kawabe, M.A. Shibata, and M. Sano Decrease of prostaglandin E2 and 5-bromo-20 deoxyuridine labeling but not prostate tumor development by indomethacin treatment of rats given 3,20-dimethyl-4 aminobiphenyl and testosterone propionate Jpn J Cancer Res 88 1997 350 355
20. S. Gupta, V.M. Adhami, and J.S. Lewin Dietary supplementation of selective COX-2 inhibitor celecoxib suppresses prostate carcinogenesis in TRAMP Mice Proc Am Assoc Cancer Res 43 2002 671
21. I. Bjarnason, J. Hayllar, and A.J. MacPherson Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans Gastroenterology 104 1993 1832 1847
22. D.A. Henry Side-effects of non-steroidal anti-inflammatory drugs Baillieres Clin Rheumatol 2 1998 425 454
23. M.D. Murray, and D.C. Brater Effects of NSAIDs on the kidney Prog Drug Res 49 1997 155 171
24. I.A. Mardini, and G.A. Fitzgerald Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs Mol Interv 1 2001 30 38
25. R.N. Dubois, S.B. Abramson, and L. Crofford Cyclooxygenase in biology and disease FASEB J 12 1998 1063 1073
26. K.M. Leahy, A.T. Koki, and J.L. Masferrer Role of cyclooxygenases in angiogenesis Curr Med Chem 7 2000 1163 1170
27. P.E. Lipsky Role of cyclooxygenase-1 and -2 in health and disease Am J Orthop 28 1999 8 12
28. S.M. Prescott, and F.A. Fitzpatrick Cyclooxygenase-2 and carcinogenesis Biochim Biophys Acta 1470 2000 69 78
29. C.H. Liu, S.H. Chang, and K.H. Narko Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice J Biol Chem 276 2001 18563 18569
30. H.F. Tiano, C.D. Loftin, and J. Akunda Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis Cancer Res 62 2002 3395 3401
31. D.K. Bol, R.B. Rowley, and C.P. Ho Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development Cancer Res 62 2002 2516 2521
32. G.P. O'Neill, and A.W. Ford-Hutchinson Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues FEBS Lett 330 1993 156 160
33. A. Gupta, M. Srivastava, and N. Ahmad Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma Prostate 42 2000 73 78
34. R. Yoshimura, H. Sano, and C. Masuda Expression of cyclooxygenase-2 in prostate carcinoma Cancer 89 2000 589 596
35. A. Kirschenbaum, A.P. Klausner, and R. Lee Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate Urology 56 2000 671 676
36. S. Madaan, P.D. Abel, and K.S. Chaudhary Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment BJU Int 86 2000 736 741
37. L.M. Lee, C.C. Pan, and C.J. Cheng Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia Anticancer Res 21 2001 1291 1294
38. P. Uotila, E. Valve, and P. Martikainen Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer Urol Res 29 2001 23 28
39. S. Zha, W.R. Gage, and J. Sauvageot Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma Cancer Res 61 2001 8617 8623
40. V. Subbarayan, A.L. Sabichi, and N. Llansa Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells Cancer Res 61 2001 2720 2726
41. S.H. Hong, I. Avis, and M.D. Vos Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors Cancer Res 59 1999 2223 2228
42. J.T. Lim, G.A. Piazza, and E.K. Han Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines Biochem Pharmacol 58 1999 1097 1107
43. R.R. Tjandrawinata, and M. Hughes-Fulford Up-regulation of cyclooxygenase-2 by product-prostaglandin E2 Adv Exp Med Biol 407 1997 163 170
44. X.H. Liu, A. Kirschenbaum, and M. Lu Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway Biochem Biophys Res Commun 290 2002 249 255
45. M. Tsujii, and R.N. DuBois Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 1995 493 501
46. X.H. Liu, S. Yao, and A. Kirschenbaum NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells Cancer Res 58 1998 4245 4249
47. A.L. Hsu, T.T. Ching, and D.S. Wang The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 275 2000 11397 11403
48. Z. Zhang, and R.N. DuBois Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor Oncogene 20 2001 4450 4456
49. M. Tsujii, S. Kawano, and S. Tsuji Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716
50. X.H. Liu, A. Kirschenbaum, and S. Yao Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line Clin Exp Metastasis 17 1999 687 694
51. J.L. Masferrer, K.M. Leahy, and A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311
52. X.H. Liu, A. Kirschenbaum, and S. Yao Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo J Urol 164 2000 820 825
53. K. Kismet, M.T. Akay, and O. Abbasoglu Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention Cancer Detect Prev 28 2004 127 142
54. C.J. Hawkey COX-2 inhibitors Lancet 353 1999 307 314
55. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group N Engl J Med 343 2000 1520 1528
56. D.J. Graham, D. Campen, and R. Hui Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 2005 475 481
57. R.S. Bresalier, R.S. Sandler, and H. Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
58. E.J. Topol Failing the public health - rofecoxib, Merck, and the FDA N Engl J Med 351 2004 1707 1709
59. M. Hudson, H. Richard, and L. Pilote Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study BMJ 330 2005 1370
60. F.E. Silverstein, G. Faich, and J.L. Goldstein Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study JAMA 284 2000 1247 1255
61. S.D. Solomon, J.J. McMurray, and M.A. Pfeffer Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
62. E.A. Swabb, D.D. Quiggle, and I. Gutierrez Multi-dose phase 1 trial of MPC-7869 in prostate cancer patients with increasing prostate specific antigen (PSA) Proc Am Assoc Cancer Res 43 2002 749 [Abstract 3714]
63. N.A. Dawson, and S.F. Slovin Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer Urology 62 Suppl. 1 2003 102 118
64. J.E. Derksen, and R.S. Pruthi COX-2 inhibitors in PSA recurrent prostate cancer: a pilot study J Urol 167 Suppl. 2002 304 [Abstract 1199]
65. D.W. Lin, and P.S. Nelson The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma Clin Prostate Cancer 2 2003 119 126